Amgen Aktie
WKN: 867900 / ISIN: US0311621009
22.05.2024 07:32:02
|
Roche: FDA Grants Breakthrough Device Designation For Bood Test Measuring Lp(a)
(RTTNews) - Swiss drug major Roche Holding AG (RHHBY) announced Wedensday that the Tina-quant lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration. It is to identify patients who may benefit from innovative Lp(a)-lowering therapy currently in development.
The blood test measuring Lp(a), a key marker for hereditary cardiovascular risk, has been developed in collaboration with Amgen (AMGN).
The company noted that Lp(a) is emerging as an important, yet under-recognised, potential risk factor for cardiovascular disease. Worldwide, around one in five people have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases.
Currently, there is no FDA authorised Lp(a) assay measuring Lp(a) in nmol/L available in the US.
The Roche Diagnostics Tina-quant Lp(a) assay measures lipoprotein (a) in a person's bloodstream. Once approved, the new Tina-quant test is expected to be made available to support the selection of patients who may benefit from an innovative Lp(a)-lowering therapy.
It will be made available on Roche's installed base of over 90,000 serum work area (SWA) systems worldwide. Roche noted that the assay will be part of its wider portfolio of tests for cardiovascular diseases.
Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at Amgen, said, "Lp(a) testing rates are markedly low, and existing lab tests may not consistently and accurately measure Lp(a) levels. By combining Amgen's deep legacy and expertise in cardiovascular disease with Roche's diagnostic expertise, we can accelerate access to more standardised testing and equip more patients and healthcare providers with important information to better understand their risk for cardiovascular disease."
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Amgen Inc.mehr Nachrichten
04.06.25 |
Schwache Performance in New York: Dow Jones schlussendlich schwächer (finanzen.at) | |
04.06.25 |
Börse New York in Grün: Dow Jones zum Handelsstart freundlich (finanzen.at) | |
02.06.25 |
Dow Jones 30 Industrial-Titel Amgen-Aktie: So viel Gewinn hätte ein Investment in Amgen von vor 3 Jahren eingebracht (finanzen.at) | |
30.05.25 |
Börse New York in Grün: Dow Jones beendet den Freitagshandel in der Gewinnzone (finanzen.at) | |
30.05.25 |
Angespannte Stimmung in New York: So steht der Dow Jones nachmittags (finanzen.at) | |
30.05.25 |
Schwacher Handel: Dow Jones am Freitagmittag mit Abgaben (finanzen.at) | |
29.05.25 |
Freundlicher Handel in New York: Dow Jones notiert zum Handelsende im Plus (finanzen.at) | |
29.05.25 |
Angespannte Stimmung in New York: Dow Jones verliert am Nachmittag (finanzen.at) |
Analysen zu Amgen Inc.mehr Analysen
Aktien in diesem Artikel
Amgen Inc. | 254,30 | 0,08% |
|
Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGSh | 35,39 | 2,00% |
|